A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer.

Margaret E Gatti-MaysJason M RedmanRenee N DonahueClaudia PalenaRavi A MadanFatima KarzaiMarijo BilusicHoussein Abdul SaterJennifer L MartéLisa M CordesSheri McMahonSeth M SteinbergAlanvin OrpiaAndrea BurmeisterJeffrey SchlomJames L GulleyJulius Strauss

Published in: The oncologist (2019)

Concurrent ETBX-011, ETBX-051, and ETBX-061 can be safely administered to patients with advanced cancer. Further studies of the vaccine regimen in combination with other agents, including immune checkpoint blockade, are planned.

Keyphrases

advanced cancer
palliative care
study protocol
phase iii
phase ii
case control
squamous cell carcinoma
open label